

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM340388

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ZIOPHARM ONCOLOGY, INC.		04/16/2015	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	SOLASIA PHARMA K.K.		
Street Address:	3F, Shiodome Building, 1-2-20		
Internal Address:	Kaigan, Minato-ku		
City:	Tokyo		
State/Country:	JAPAN		
Postal Code:	105-0022		
Entity Type:	CORPORATION: JAPAN		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	3880259	ZINAPAR	
CORRESPONDENCE DATA			
Fax Number:	6173957070		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	617-395-7019		
Email:	alhtrademarks@lalaw.com		
Correspondent Name:	Ann Lamport Hammitte		
Address Line 1:	One Main Street, 11th Floor		
Address Line 4:	Cambridge, MASSACHUSETTS 02142		
ATTORNEY DOCKET NUMBER:	S2191-2000		
DOMESTIC REPRESENTATIVE			
Name:	Ann Lamport Hammitte		
Address Line 1:	One Main Street, 11th Floor		
Address Line 2:	Lando & Anastasi, LLP		
Address Line 4:	Cambridge, MASSACHUSETTS 02142		
NAME OF SUBMITTER:	Ann Lamport Hammitte		
SIGNATURE:	//alh//		

CH \$40.00 3880259

DATE SIGNED:	05/05/2015
Total Attachments: 3 source=Executed Confirmatory Trademark Assignment; (S2191-4000) ZIOPHARM to SOLASIA#page1.tif source=Executed Confirmatory Trademark Assignment; (S2191-4000) ZIOPHARM to SOLASIA#page2.tif source=Executed Confirmatory Trademark Assignment; (S2191-4000) ZIOPHARM to SOLASIA#page3.tif	


CONFIRMATORY TRADEMARK ASSIGNMENT

WHEREAS, ZIOPHARM Oncology, Inc., a Delaware corporation having a place of business at 1 First Avenue, Parris Building, #34, Navy Yard Plaza, Boston, Massachusetts 02129-4236, USA (hereinafter referred to as "Assignor"), is the owner of record of the marks shown on the attached Schedule A, (hereinafter referred to as "the Marks"); and

WHEREAS, pursuant to an Assignment and Assumption Agreement entered into effective July 31, 2014, Solasia Pharma K.K., a Japanese corporation having its legal address at 3F, Shiodome Building, 1-2-20, Kaigan, Minato-ku, Tokyo 105-0022, Japan (hereinafter referred to as "Assignee"), acquired the Marks of Assignor, including the entire right, title and interest in and to the Marks, and the goodwill of the business associated with the Marks;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency which are acknowledged, Assignor does hereby acknowledge and confirm the Assignment on July 31, 2014 unto Assignee of the entire right, title and interest in and to the Marks, the Registrations thereof, the goodwill of the business associated with the Marks, and the right to recover for past infringement.

ZIOPHARM ONCOLOGY, INC.



Date: 16 MAR 15

Name: Caesar Belbel
Title: EVP, Chief Legal Officer

Commonwealth of Massachusetts) ss.
County of: Suffolk)

On this 16 day of April, 2015, before me, the undersigned Notary Public, personally appeared Caesar Belbel, provided to me through satisfactory evidence of identification, which were MA Drivers License, to be the person whose name is signed on the above document in my presence.




Heather L. Wheelble
(official signature and seal of Notary)
My commission expires: _____

My Commission Expires
October 24, 2019

Accepted and acknowledged:


SOLASIA PHARMA K.K.

Date: April 14, 2015


Name: Yoshinori Arai
Title: President


Witness 1:

Date: April 15, 2015


Name: Toshio Miyashita
Title: CFO

Witness 2:

Date: April 15, 2015


Name: Hisako Otsuki
Title: VP, Administration Div.

Schedule A

Mark	Country	Classes	Registration No.	Reg. Date	Our Ref.
ZINAPAR	China	05	973901	30-Jul-2008	S2191-2000CN
ZINAPAR	European Community	05	006380349	25-Jul-2008	S2191-2000EM
ZINAPAR	India	05	1720187	21-Nov-2011	S2191-2000IN
ZINAPAR	Int'l Registration Madrid Protocol	05	973901	30-Jul-2008	S2191-2000WP
ZINAPAR	Israel	05	213784	13-Apr-2010	S2191-2000IL
ZINAPAR	Japan	05	5134275	09-May-2008	S2191-2000JP
ZINAPAR	Korea	05	973901	30-Jul-2008	S2191-2000KR
ZINAPAR	Mexico	05	1076050	04-Dec-2008	S2191-2000MX
ZINAPAR	Russia	05	973901	30-Jul-2008	S2191-2000RU
ZINAPAR	Singapore	05	973901	30-Jul-2008	S2191-2000SG
ZINAPAR	Taiwan	05	1357565	16-Apr-2009	S2191-2000TW
ZINAPAR	United States	05	3,880,259	23-Nov-2010	S2191-2000
ARINAPAR	European Community	05	006380208	25-Jul-2008	S2191-2001EM

2265895.1